StockData
Kyverna Therapeutics, Inc. logo

Kyverna Therapeutics, Inc. (KYTX) stock

KYTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$4.48−0.22 (-4.68%)

Close on Nov 18, 2026Market cap $277.06MP/E –Yield –

Kyverna Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Kyverna Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$150.80M. For fiscal 2025 it was -$153.71M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$153.71M–
FY2024Dec 31, 2024-$114.25M–
FY2023Dec 31, 2023-$52.41M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$35.37M–
Q2 FY2026Jun 30, 2026-$40.31M–
Q1 FY2026Mar 31, 2026-$41.60M–
Q4 FY2025Dec 31, 2025-$33.53M–
Q3 FY2025Sep 30, 2025-$43.32M–
Q2 FY2025Jun 30, 2025-$31.95M–
Q1 FY2025Mar 31, 2025-$44.92M–
Q4 FY2024Dec 31, 2024-$37.06M–
Q3 FY2024Sep 30, 2024-$27.49M–
Q2 FY2024Jun 30, 2024-$24.18M–
Q1 FY2024Mar 31, 2024-$25.53M–
Q4 FY2023Dec 31, 2023-$18.56M–
Q3 FY2023Sep 30, 2023-$11.13M–
Q2 FY2023Jun 30, 2023-$11.26M–
Q1 FY2023Mar 31, 2023-$11.46M–

More Kyverna Therapeutics figures

See a number that looks wrong?